
AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own ESAB, you need to be comfortable with a cyclical, globally exposed welding and cutting business that is leaning into acquisitions and automation. The finance leadership reshuffle, including a new CFO and CAO, does not appear to alter the near term focus on integrating Eddyfi and managing tariff and emerging market pressures, which remain key catalysts and risks for earnings and cash generation.
The most relevant recent announcement here is ESAB’s US$1,000,000,000 senior notes due 2031, earmarked to help fund the Eddyfi acquisition. This financing move underlines how important successful integration of Eddyfi is to the story, especially as ESAB balances higher leverage with exposure to tariffs, protectionism and cyclical swings in industrial capex.
But investors should also be aware that rising protectionism and trade frictions could still...
Read the full narrative on ESAB (it's free!)
ESAB's narrative projects $3.2 billion revenue and $452.8 million earnings by 2029.
Uncover how ESAB's forecasts yield a $148.00 fair value, a 50% upside to its current price.
One Simply Wall St Community member currently pegs ESAB’s fair value at US$148 per share, offering a single but detailed independent view. You should weigh that against ESAB’s tariff and trade policy exposure, which could affect how the business performs relative to any fair value estimate.
Explore another fair value estimate on ESAB - why the stock might be worth as much as 50% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com